CTOs on the Move

Ring Therapeutics

www.ringtx.com

 
Ring`s research team has uncovered the world`s largest collection of commensal anelloviruses and are harnessing these natural viruses to target a wide array of diseases with significant unmet need. The unique biology of anelloviruses provides a foundation for a revolutionary new platform and a new class of programmable medicines.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ringtx.com
  • 620 Memorial Drive Suite 300
    Cambridge, MA USA 02139
  • Phone: 202.824.5050

Executives

Name Title Contact Details
John Huynh
Senior Vice President of Technical Operations Profile
Konstantin Konstantinov
Chief Technology Officer Profile

Similar Companies

Applied Molecular Transport

Applied Molecular Therapeutics (AMT), a public biopharmaceutical company based in South San Francisco, California, is committed to developing novel, oral biological therapeutics to treat severe autoimmune, metabolic and inflammatory diseases. AMT is leveraging its propriety technology platforms to create gastrointestinal (GI)-select therapeutics that harness naturally occurring transport and targeting mechanisms to cross the protective barrier of the intestinal epithelium (IE). Once across the IE, the therapeutics gain privileged access to the immune cell-rich environment of the GI tissue as well as the hepatic portal system and downstream systemic circulation. With this privileged access, AMT`s goal is to develop transformative new oral therapeutic treatment options that offer patients greater efficacy and tolerability than available with today`s therapeutics. AMT has a robust pipeline of oral biologic product opportunities, including AMT-101 which is currently in Phase 1b clinical development for the treatment of adults with ulcerative colitis (UC). AMT-101 is a novel, gut-selective, investigational oral biologic fusion protein of interleukin 10 (IL-10), an anti-inflammatory cytokine. Derived from AMT`s proprietary platforms, AMT-101 is engineered to cross the selective barrier of the IE and enhance localized IL-10 directly within the immune-cell rich environment of GI tissue where up to 75 percent of immune cells reside. This direct targeting of the immune system creates the potential for AMT-101 to address, at its point of origin, the immune dysregulation that gives rise to UC and other inflammatory bowel diseases, and restore immune homeostasis with minimal systemic exposure and potentially fewer adverse events compared to systemic administration of IL-10. AMT has amassed a broad global IP portfolio surrounding its multiple technology platforms and therapeutic programs.

InCarda Therapeutics

InCarda Therapeutics is a clinical stage drug delivery company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route.

Lifetree Pain Clinic

Lifetree Pain Clinic is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ABR--Affinity BioReagents

ABR--Affinity BioReagents is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genome British Columbia

Genome British Columbia is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.